UBS Group
GDTC icon

UBS Group’s CytoMed Therapeutics GDTC Stock Holding History

UBS Group’s Portfolio GDTC Stock Details GDTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.98K Sell
4,831
-1,351
-22% -$1.4K ﹤0.01% 8991
2026
Q1 		$6.18K Buy
6,182
+5,117
+480% +$5.39K ﹤0.01% 8709
2025
Q4 		$1.42K Sell
1,065
-12,224
-92% -$23.7K ﹤0.01% 9591
2025
Q3 		$26.4K Sell
13,289
-4,292
-24% -$8.42K ﹤0.01% 7981
2025
Q2 		$39.6K Buy
17,581
+3,134
+22% +$7.14K ﹤0.01% 7962
2025
Q1 		$31.5K Buy
14,447
+4,349
+43% +$11.5K ﹤0.01% 7908
2024
Q4 		$34.3K Buy
10,098
+10,037
+16,454% +$24.1K ﹤0.01% 7526
2024
Q3 		$96 Buy
+61
New +$106 ﹤0.01% 9162
2024
Q1 		– Sell
-3,500
Closed -$17.1K – 9569
2023
Q4 		$17.1K Buy
3,500
+3,023
+634% +$11.4K ﹤0.01% 7198
2023
Q3 		$1.67K Buy
477
+423
+783% +$1.6K ﹤0.01% 7860
2023
Q2 		$165 Buy
+54
New +$168 ﹤0.01% 8432

Other funds holding GDTC

AIM
Axiom Investment Management New York $150M AUM
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

UBS Group's GDTC Position: Q2 2026 in Review

UBS Group reduced its CytoMed Therapeutics (GDTC) stake by 22% in Q2 2026, selling an estimated $1.4K and leaving 4,831 shares worth $4.98K. The position accounts for ﹤0.01% of the portfolio, ranked #8991.

UBS Group first reported a position in GDTC in Q2 2023 and has held it in 11 quarters since. The position peaked at $39.6K in Q2 2025. 3 funds tracked by Wall St. Rank hold GDTC as of Q2 2026.

  • UBS Group held 4,831 shares of CytoMed Therapeutics worth $4.98K as of Q2 2026.
  • UBS Group sold 1,351 CytoMed Therapeutics shares in Q2 2026, an estimated $1.4K.
  • CytoMed Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q2 2026, its #8991 holding.
  • UBS Group first reported a position in CytoMed Therapeutics in Q2 2023 and has held it in 11 quarters since.
  • UBS Group's CytoMed Therapeutics position peaked at $39.6K in Q2 2025.
  • 3 funds tracked by Wall St. Rank held CytoMed Therapeutics as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.